WO1999065873A1 - Separation of epsilon caprolactam from isomers - Google Patents

Separation of epsilon caprolactam from isomers Download PDF

Info

Publication number
WO1999065873A1
WO1999065873A1 PCT/US1999/013407 US9913407W WO9965873A1 WO 1999065873 A1 WO1999065873 A1 WO 1999065873A1 US 9913407 W US9913407 W US 9913407W WO 9965873 A1 WO9965873 A1 WO 9965873A1
Authority
WO
WIPO (PCT)
Prior art keywords
epsilon caprolactam
caprolactam
adsorbent
ethyl
isomers
Prior art date
Application number
PCT/US1999/013407
Other languages
English (en)
French (fr)
Inventor
Jay Fingeret Miller
George Ernest Ii Keller
Original Assignee
Union Carbide Chemicals & Plastics Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/094,651 external-priority patent/US6045703A/en
Priority claimed from US09/094,650 external-priority patent/US6036865A/en
Application filed by Union Carbide Chemicals & Plastics Technology Corporation filed Critical Union Carbide Chemicals & Plastics Technology Corporation
Priority to JP2000554700A priority Critical patent/JP2002518372A/ja
Priority to CA002335114A priority patent/CA2335114A1/en
Priority to BR9911231-0A priority patent/BR9911231A/pt
Priority to KR1020007013928A priority patent/KR20010052680A/ko
Priority to AU50825/99A priority patent/AU5082599A/en
Priority to EP99935319A priority patent/EP1087942A1/en
Publication of WO1999065873A1 publication Critical patent/WO1999065873A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D201/00Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/16Separation or purification

Definitions

  • This invention relates to a process for separating epsilon caprolactam from a feed mixture comprising epsilon caprolactam and at least one additional hydrocarbon selected from the group consisting of 4-ethyl-2-pyrrolidinone, 5-methyl-2-piperdinone, 3-ethyl-2- pyrrolidinone and 3-methyl-2-piperdinone.
  • Epsilon caprolactam is a valuable intermediate which is useful, for example, in the production of nylon 6.
  • Certain processes used to produce epsilon caprolactam generate isomer byproducts, e.g., 4-ethyl-2-pyrrolidinone, 5-methyl-2-piperdinone, 3-ethyl-2-pyrrolidinone and 3-methyl-2-piperdinone, some of which exhibit less than a 1°C difference in vapor pressure at 10 mm Hg (absolute) compared with caprolactam.
  • Conventional separation techniques such as distillation are not effective for separating such mixtures. Accordingly, it would be desirable to separate epsilon caprolactam from its isomer byproducts to give high purity epsilon caprolactam.
  • This invention relates in part to a process for separating epsilon caprolactam from a feed mixture comprising epsilon caprolactam and one or more epsilon caprolactam isomers selected from the group consisting of 4-ethyl-2-pyrrolidinone, 5-methyl-2- piperdinone, 3-ethyl-2-pyrrolidinone and 3-methyl-2-piperdinone or octahydrophenazine which process comprises contacting under adsorption conditions said mixture with an adsorbent, selectively adsorbing said epsilon caprolactam isomers or octahydrophenazine to substantial exclusion of said epsilon caprolactam, removing the non- adsorbed portion of the feed mixture from contact with the adsorbent, and thereafter recovering high purity epsilon caprolactam.
  • the epsilon caprolactam isomers or octahydrophenazine can be recovered by desorption under desorption conditions.
  • the process can be conducted in a batch or semi-batch manner or in a continuous manner using moving bed or simulated moving bed technologies.
  • This invention also relates in part to a process for separating epsilon caprolactam from a mixture comprising epsilon caprolactam and one or more epsilon caprolactam isomers selected from the group consisting of 4-ethyl-2-pyrrolidinone, 5-methyl-2- piperdinone, 3-ethyl-2-pyrrolidinone and 3-methyl-2-piperdinone or octahydrophenazine which process comprises providing an initial solution containing a non-eutectic mixture of epsilon caprolactam and one or more epsilon caprolactam isomers selected from the group consisting of 4-ethyl-2-pyrrolidinone, 5-methyl-2-piperdinone, 3-ethyl- 2-pyrrolidinone and 3-methyl-2-piperdinone or octahydrophenazine, which mixture has a composition in the compositional region where only epsilon caprolactam crystallize
  • Fig. 1 graphically depicts the elution of caprolactam and its isomers, i.e., 4-ethyl-2-pyrrolidinone and 5-methyl-2-piperdinone, from a silicalite column using methanol as the solvent at 80°C.
  • Fig. 3 graphically depicts the elution of caprolactam and its isomers from a silicalite column using methanol as the solvent and 1% triethylamine at 110°C. Caprolactam is clearly separated from the isomers. The increased temperature gives better separation.
  • Fig. 4 graphically depicts the elution of caprolactam and its isomers from a silicalite column using acetonitrile as the solvent at 120°C. Caprolactam is clearly separated from the isomers.
  • Fig. 5 graphically depicts the elution of caprolactam and its isomers from a silicalite column using acetonitrile as the solvent and 1% triethylamine at 120°C. Caprolactam is clearly separated from the isomers.
  • Fig. 6 graphically depicts the elution of caprolactam and its isomers from a silicalite column using acetonitrile as the solvent at 150°C. Caprolactam is clearly separated from the isomers.
  • Fig. 7 graphically depicts the elution of caprolactam and its isomers from a silicalite column using methyl acetate as the solvent at 100°C. Caprolactam is clearly separated from the isomers.
  • Fig. 8 graphically depicts the elution of caprolactam and its isomers from a silicalite column using methyl acetate as the solvent and 1% triethylamine at 100°C. Caprolactam is clearly separated from the isomers.
  • Fig. 9 graphically depicts the elution of caprolactam and its isomers from a carbon F400 column using methanol as the solvent at 80°C. Caprolactam elutes earlier than the isomers.
  • Fig. 10 is a phase diagram illustrating the phenomena involved in the practice of this invention when conglommerates are involved.
  • Fig. 11 depicts a reaction flow scheme where the desired species is non-retentive and melt crystallization is used.
  • Fig. 12 depicts a reaction flow scheme where the desired species is non-retentive and solution crystallization is used. In comparison with Fig. 11, another solvent reclamation column is added.
  • Fig. 13 depicts a reaction flow scheme where the extract contains the desired species and solution crystallization is used. In comparison with Fig. 12, the raffinate and extract streams are switched.
  • Fig. 14 depicts a reaction flow scheme where the extract contains the desired species and melt crystallization is used.
  • Fig. 15 graphically depicts results from solution crystallization using acetone as a solvent and showing fraction recovery and purity of caprolactam at various temperatures.
  • Fig. 16 graphically depicts the solubility of caprolactam in methanol.
  • Fig. 17 graphically depicts results comparing the starting solution of caprolactam with the purity of caprolactam in the collected crystals using methanol as a solvent.
  • Fig. 18 graphically depicts the solubility of caprolactam in acetonitrile.
  • Fig. 19 graphically depicts results comparing the starting solution of caprolactam with the purity of caprolactam in the collected crystals using acetonitrile as a solvent.
  • this invention relates to a process for separating epsilon caprolactam from a feed mixture comprising epsilon caprolactam and at least one other hydrocarbon from the group consisting of 4-ethyl-2-pyrrolidinone, 5-methyl-2-piperdinone, 3-ethyl- 2-pyrrolidinone and 3-methyl-2- ⁇ iperdinone or octahydrophenazine.
  • the process comprises contacting in liquid phase under adsorption conditions, the feed with an adsorbent comprising activated carbon, molecular sieve carbon, molecular sieve or zeolite which selectively adsorbs epsilon caprolactam isomers or octahydrophenazine.
  • the feed is then removed from the adsorbent, and the epsilon caprolactam is recovered in high purity.
  • the epsilon caprolactam isomers or octahydrophenazine can be recovered by desorption under desorption conditions with a desorbent material comprising a hydrocarbon or water.
  • the individual components of the feed mixture and the desorbent material have boiling points of at least 5°C difference.
  • this invention relates to a process for separating epsilon caprolactam from a feed mixture comprising epsilon caprolactam and one or more epsilon caprolactam isomers selected from the group consisting of 4-ethyl-2-pyrrolidinone, 5-methyl-2-piperdinone, 3-ethyl-2-pyrrolidinone and 3-methyl-2- piperdinone or octahydrophenazine which process comprises contacting under adsorption conditions said mixture with an adsorbent, selectively adsorbing said epsilon caprolactam to substantial exclusion of said epsilon caprolactam isomers or octahydrophenazine, removing the non-adsorbed portion of the feed mixture from contact with the adsorbent, and thereafter recovering high purity epsilon caprolactam by desorption under desorption conditions.
  • the process can also be conducted in a batch or semi-batch
  • a further optional step involves crystallizing the epsilon caprolactam from a solution thereof so as to isolate the desired epsilon caprolactam in an even purer form as described hereinbelow. Crystallization may also be employed solely as described hereinbelow.
  • Other embodiments of this invention encompass details about feed mixtures, desorbents, flow schemes and operating conditions, all of which are hereinafter disclosed in the following discussion of each of the facets of this invention. At the outset the definitions of various terms used throughout this specification will be useful in making clear the operation, objects and advantages of the present invention.
  • feed mixture is a mixture containing one or more extract components and one or more raffinate components to be fed to an adsorbent of the process, i.e., epsilon caprolactam isomers and epsilon caprolactam.
  • feed stream indicates a stream of feed mixture which passes to an adsorbent used in the process.
  • extract component is a type of compound or a compound that is more selectively adsorbed by the adsorbent while a “raffinate component” is a compound or type of compound that is less selectively adsorbed.
  • epsilon caprolactam isomers are the extract component and epsilon caprolactam is the raffinate component.
  • raffinate stream or "raffinate output stream” means a stream through which a raffinate component is removed from an adsorbent.
  • the composition of the raffinate stream can vary from essentially 100% desorbent material (hereinafter defined) to essentially 100% raffinate components.
  • extract stream or "extract output stream” shall mean a stream through which an extract material which has been desorbed by a desorbent material is removed from the adsorbent.
  • the composition of the extract stream likewise, can vary from essentially 100% desorbent material to essentially 100% extract components.
  • high-purity extract product hereinafter defined
  • a raffinate product hereinafter defined
  • the extract and raffinate streams then are further distinguished from each other and from the feed mixture by the ratio of the concentrations of an extract component and a specific raffinate component, both appearing in the particular stream.
  • the ratio of concentration of the more selectively adsorbed epsilon caprolactam isomers to the concentration of the less selectively adsorbed epsilon caprolactam will be highest in the extract stream, next highest in the feed mixture, and lowest in the raffinate stream.
  • the ratio of the less selectively adsorbed epsilon caprolactam to the more selectively adsorbed epsilon caprolactam isomers will be highest in the raffinate stream, next highest in the feed mixture, and the lowest in the extract stream.
  • desorbent material or "desorbent solvent” shall mean generally a material capable of desorbing an extract component.
  • desorbent stream or "desorbent input stream” indicates the stream through which desorbent material passes to the adsorbent.
  • separation means typically fractionators, where at least a portion of desorbent material will be separated at separation conditions to produce an extract product and a raffinate product.
  • extract product and raffinate product mean products produced by the process containing, respectively, an extract component and a raffinate component in higher concentrations than those in the respective extract stream and the raffinate stream.
  • the epsilon caprolactam described herein is useful in a variety of applications, such as the manufacture of synthetic fibers (especially nylon 6), plastics, bristles, film, coatings, synthetic leather, plasticizers and paint vehicles, crosslinking agent for polyurethanes, synthesis of amino acid lysine and the like.
  • Preferred processes include pentenoic acid salt routes to epsilon caprolactam as described in copending U.S. Patent Application Serial No. 08/839,576, filed April 15, 1997, pentenol routes to epsilon caprolactam as described in copending U.S. Patent Application Serial No. 08/843,340, filed April 15, 1997, and other routes to epsilon caprolactam as described in copending U.S. Patent Application Serial No. 09/094,651, filed June 15, 1998, the disclosures of which are incorporated herein by reference.
  • Other processes include the Beckman rearrangement of cyclohexanone oxime to epsilon caprolactam as disclosed in U.S. Patent Nos.
  • the epsilon caprolactam compositions can be prepared without the need for separating less stable intermediates such as isomers of formylvaleric acids or salts or, isomers of hydroxyhexanal, and without the need for elaborate separation processes on less stable molecules. This allows for separation at more desirable points in a process for producing epsilon caprolactam thus allowing for improved efficiencies.
  • Certain conversion processes for epsilon caprolactam yield a product which also contains other closely boiling epsilon caprolactam isomers, e.g., 4-ethyl-2-pyrrolidmone, 5-methyl-2-piperdinone, 3-ethyl- 2-pyrrolidinone and 3-methyl-2-piperdinone.
  • other closely boiling epsilon caprolactam isomers e.g., 4-ethyl-2-pyrrolidmone, 5-methyl-2-piperdinone, 3-ethyl- 2-pyrrolidinone and 3-methyl-2-piperdinone.
  • Isolation and purification of epsilon caprolactam to polymerization grade quality is important due to its principal use in the production of nylon 6 by a polymerization procedure.
  • impurities pose significant problems due to the sensitivity of such procedures to contamination.
  • This invention simplifies purification procedures by providing a simple and effective method of removing epsilon caprolactam from certain epsilon caprolactam isomers, e.g., 4-ethyl-2- pyrrolidinone, 5-methyl-2-piperdinone, 3-ethyl-2-pyrrolidinone and 3- methyl-2-piperdinone.
  • an appropriate feed mixture for practicing this invention comprises epsilon caprolactam, 4-ethyl-2-pyrrolidinone, 5-methyl-2- piperdinone, 3-ethyl-2-pyrrolidinone and 3-methyl-2-piperdinone whether alone or in combination.
  • feed mixtures can also contain minor portions of other similar boiling point hydrocarbons which may be removed from either the extract or raffinate.
  • suitable feed mixtures can also contain minor portions of other similar boiling point hydrocarbons which may be removed from either the extract or raffinate.
  • Typical sources for the feed mixture of this invention are the processes identified above.
  • Preferred feed mixtures useful in this invention include those disclosed in copending U.S. Patent Application Serial No. 08/956,745, filed October 23, 1997, the disclosure of which is incorporated herein by reference.
  • the mixture is contacted with the adsorbent and the epsilon caprolactam isomers are more selectively adsorbed and retained by the adsorbent while the other components of the feed mixture are relatively unadsorbed and are removed from the interstitial void spaces between the particles of adsorbent and the surface of the adsorbent.
  • the adsorbent containing the more selectively adsorbed epsilon caprolactam isomers is referred to as a "rich" adsorbent.
  • the epsilon caprolactam isomers are then recovered from the rich adsorbent by contacting the rich adsorbent with a desorbent material.
  • desorbent material or "desorbent solvent” as used herein shall mean any fluid substance capable of removing a selectively adsorbed feed component from the adsorbent.
  • desorbent material selection is not too critical and desorbent materials comprising gaseous hydrocarbons such as methane, ethane, etc., or other types of gases such as nitrogen or hydrogen may be used at elevated temperatures or reduced pressures or both to effectively purge the adsorbed feed component from the adsorbent.
  • the desorbent material relied upon must be judiciously selected to satisfy several criteria.
  • the desorbent material must displace the extract components from the adsorbent with reasonable mass flow rates without itself being so strongly adsorbed as to unduly prevent the extract component from displacing the desorbent material in a following adsorption cycle.
  • the selectivity it is preferred that the adsorbent be more selective for the extract component with respect to a raffinate component than it is for the desorbent material with respect to a raffinate component.
  • desorbent materials must be compatible with the particular adsorbent and the particular feed mixture. More specifically, they must not reduce or destroy the critical selectivity of the adsorbent for the extract components with respect to the raffinate component.
  • Desorbent materials to be used in the process of this invention should additionally be substances which are easily separable from the feed mixture that is passed into the process.
  • both desorbent material and the extract components are typically removed in admixture from the adsorbent.
  • one or more raffinate components is typically withdrawn from the adsorbent in admixture with desorbent material and without a method of separating at least a portion of desorbent material, such as distillation, neither the purity of the extract product nor the purity of the raffinate product would be very high. It is therefore contemplated that any desorbent material used in this process will have a substantially different boiling point than that of any individual components of the feed mixture to allow separation of desorbent material from feed components in the extract and raffinate streams by simple fractionation thereby permitting reuse of desorbent material in the process.
  • substantially different shall mean that the difference between the boiling points of the desorbent material and the individual components of the feed mixture shall be at least about 5°C.
  • the boiling range of the desorbent material may be higher or lower than that of the feed mixture, preferably lower than that of the feed mixture.
  • the effective desorbent materials comprise hydrocarbons, particularly aliphatic and aromatic hydrocarbons having less than eight carbon atoms, or water.
  • Illustrative desorbents useful in this invention include, for example, methanol, ethyl ether, cyclopentane, acetone, methyl acetate, isopropyl ether, hexane, methyl cyclopentane, ethyl acetate, ethanol, benzene, cyclohexane, acetonitrile, propanol, propionitrile, water, toluene, cycloheptane, ethylbenzene, p-xylene and cyclooctane.
  • adsorbents are highly desirable, if not absolutely necessary, to the successful operation of a selective adsorption process. Among such characteristics are adsorptive capacity for some volume of an extract component per volume of adsorbent, the selective adsorption of an extract component with respect to a raffinate component and the desorbent material, and sufficiently fast rates of adsorption and desorption of the extract components to and from the adsorbent.
  • Capacity of the adsorbent for adsorbing a specific volume of one or more extract components is, of course, a necessity; without such capacity the adsorbent is useless for adsorptive separation. Furthermore, the higher the adsorbent's capacity for an extract component the better is the adsorbent. Increased capacity of a particular adsorbent makes it possible to reduce the amount of the adsorbent needed to separate the extract component contained in a particular charge rate of feed mixture. A reduction in the amount of adsorbent required for a specific adsorptive separation reduces the cost of the separation process. It is important that the good initial capacity of the adsorbent be maintained during actual use in the separation process over some economically desirable life.
  • the second necessary adsorbent characteristic is the ability of the adsorbent to separate components of the feed; or, in other words, that the adsorbent possesses adsorptive selectivity, (B), for one component as compared to another component.
  • Relative selectivity can be expressed not only for one feed component as compared to another but can also be expressed between any feed mixture component and the desorbent material.
  • the selectivity, (B), as used throughout this specification is defined as ratio of the two components of the adsorbed phase over the ratio of the same two components of the unadsorbed phase at equilibrium conditions.
  • Equation 1 Relative selectivity is shown as Equation 1 below:
  • C and D are two components of the feed represented in volume percent and the subscripts A and U represent the adsorbed and unadsorbed phases respectively.
  • the equilibrium conditions are determined when the feed passing over a bed of adsorbent does not change composition after contacting the bed of adsorbent. In other words, there is no net transfer of material occurring between the unadsorbed and adsorbed phases.
  • a (B) larger than 1.0 indicates preferential adsorption of component C within the adsorbent.
  • a (B) less than 1.0 would indicate that component D is preferentially adsorbed leaving an unadsorbed phase richer in component C and an adsorbed phase richer in component D.
  • desorbent materials should have a selectivity equal to about 1 or less than 1 with respect to all extract components so that all of the extract components can be extracted as a class and all raffinate components clearly rejected into the raffinate stream.
  • the third important characteristic is the rate of exchange of the extract component of the feed mixture material, or in other words, the relative rate of desorption of the extract component.
  • This characteristic relates directly to the amount of desorbent material that must be employed in the process to recover the extract component from the adsorbent; faster rates of exchange reduce the amount of desorbent material needed to remove the extract component and therefore permit a reduction in the operating cost of the process. With faster rates of exchange, less desorbent material has to be pumped through the process and separated from the extract stream for reuse in the process. As illustrated in the figures, the rate of exchange of an extract component with the desorbent is related to the width of the peak envelopes usually measured at half intensity.
  • a fourth important property of the adsorbent is the absence of reactivity or catalytic function that would cause undesirable chemical changes to the feed and desorbent components.
  • Zeolitic materials are known to react with hydrocarbons, particularly olefins.
  • the carbon adsorbents of this invention are chemically inert to the components of the process streams.
  • a dynamic testing apparatus In order to test various adsorbents and desorbent material with a particular feed mixture to measure the adsorbent characteristics of adsorptive capacity and selectivity and exchange rate, a dynamic testing apparatus is employed.
  • the apparatus consists of an adsorbent chamber of approximately 70 cubic centimeter volume having inlet and outlet portions at opposite ends of the chamber.
  • the chamber is contained within a temperature control means and, in addition, pressure control equipment is used to operate the chamber at a constant predetermined pressure.
  • Chromatographic analysis equipment can be attached to the outlet line of the chamber and used to analyze "on-stream" the effluent stream leaving the adsorbent chamber or samples can be removed from the apparatus for chromatographic analysis.
  • a pulse test performed using this apparatus and the following general procedure, is used to determine selectivities and other data for various adsorbent systems.
  • the adsorbent is filled to equilibrium with a particular desorbent by passing the desorbent material through the adsorbent chamber.
  • a pulse feed containing known concentrations of the particular epsilon caprolactam isomers all diluted in desorbent is injected.
  • Desorbent flow is resumed and the feed isomers are eluted as in a liquid-solid chromatographic operation.
  • the effluent can be analyzed by on stream chromatographic equipment and traces of the envelopes of corresponding component peaks developed.
  • effluent samples can be collected periodically and later analyzed separately by gas chromatography.
  • adsorbent performance can be rated in terms of capacity index for an extract component, selectivity for one isomer with respect to another, and the rate of desorption of an extract component by the desorbent.
  • the capacity index may be characterized by the distance between the center of the peak envelope of the selectively adsorbed component and some other known reference point. It is expressed in terms of the volume in cubic centimeters of desorbent pumped during this time interval.
  • Selectivity, (B), for an extract component with respect to a raffinate component may be characterized by the ratio of the distance between the center of an extract component peak envelope and the tracer peak envelope (or other reference point) to the corresponding distance between the center of a raffinate component peak envelope and the tracer peak envelope.
  • the rate of exchange of an extract component with the desorbent can generally be characterized by the width of the peak envelopes at half intensity . The narrower the peak width the faster the desorption rate.
  • the desorption rate can also be characterized by the distance between the center of the tracer peak envelope and the disappearance of an extract component which has just been desorbed. This distance is again the volume of desorbent pumped during this time interval.
  • the adsorbent used in the process of this invention comprises any adsorbent that selectively adsorbs epsilon caprolactam isomers to substantial exclusion of epsilon caprolactam or selectively adsorbs epsilon caprolactam to substantial exclusion of octahydrophenazine.
  • Suitable adsorbents include, for example, activated carbon, molecular sieve carbon, and molecular sieves of the zeolitic variety, i.e., zeolites, and the non-zeolitic variety, i.e., molecular sieves.
  • Suitable adsorbents include those permissible adsorbents described in Kirk-Othmer, Encyclopedia of Chemical Technology, Fourth Edition, 1996, the pertinent portions of which are incorporated herein by reference.
  • Activated carbon is a common, commercially available material, such as Calgon Corporation's "Type F400" granular carbon, "PURASIV, Type PCB as described in Calgon's brochure No. 23- 108a, dated August 1978, incorporated herein by reference, is an activated carbon having a large micropore volume, the range of 15 to 20 Angstrom units in diameter, permeated by a system of macropores larger than 1000 Angstroms in diameter.
  • PURASIV is a beaded activated carbon made from molten petroleum pitch shaped into spherical particles and subsequently carbonized and activated.
  • molecular sieve carbon as used herein is not intended to necessarily distinguish from those materials referred to as “activated carbon” but to ensure that no material effective for use in the present invention is excluded. There is considerable overlap between the two terms in question and probably in most instances, for purposes of the present invention, the terms are interchangeable.
  • the particular molecular sieve carbons useful in this invention are those having an average pore size greater than about 5 Angstrom units and less than about 10 Angstrom units, preferably between about 5.2 and about 8 Angstrom units, and more preferably between about 5.5 and about 6.5 Angstrom units.
  • the adsorbent to be used in the process of this invention may also comprise molecular sieves of the zeolitic variety, i.e., zeolites, and molecular sieves of the non-zeolitic variety, i.e., molecular sieves.
  • Illustrative zeolites useful in this invention include, for example, LZ- 10, LZ-20, 4A, 5A, 13X, 10X, Y, SK40, SK41, chabazite, faujasite, levynite, gismondine, erionite, sodalite, analcime, gmelinite, harmotome, mordenite, epistilbite, heulandite, stilbite, edingtonite, mesolite, natrolite, scolecite, thomsonite, brewsterite, laumontite, phillipsite, the ZSM's (ZSM-5, ZSM-20, ZSM-12, and ZSM-34), and the like.
  • ZSM's ZSM-5, ZSM-20, ZSM-12, and ZSM-34
  • Illustrative zeolites useful in this invention are disclosed in U.S. Patent Nos. 3,702,886, 3,972,983, 3,832,449, 4,086,186 and 3,308,069, the disclosure of which are incorporated herein be reference.
  • Illustrative molecular sieves useful in this invention include, for example, the silica molecular sieves, such as silicalite (S115) as depicted in U.S. Patent Nos. 4,061,724 and 4,073,865, the disclosures of which are incorporated herein by reference.
  • molecular sieves useful in this invention include crystalline microporous molecular sieve oxides that are based on the presence of aluminophosphate in the framework of the crystal structures, e.g., those commonly known by the acronyms SAPO, MeAPO, FAPO, MAPO, MnAPO, CoAPO, ZAPO, MeAPSO, FAPSO, MAPSO, MnAPSO, CoAPSO, ZAPSO, E1APO, E1APSO and the like.
  • Such molecular sieves are described, for example, in U.S. Patent Nos. 4,567,029, 4,440,871, 4,500,651, 4,554,143 and 4,310,440, the disclosures of which are incorporated herein by reference.
  • the zeolite and molecular sieve adsorbents preferably have a pore size greater than about 5 Angstrom units and less than about 10 Angstrom units, preferably between about 5.2 and about 8 ⁇ .ngstrom units, and more preferably between about 5.5 and about 6.5 Angstrom units.
  • the adsorbents may contain meso- and macro-pores along with the preferred pore sizes. It has been discovered by this invention that certain adsorbents will adsorb the isomers of epsilon caprolactam to substantial exclusion of epsilon caprolactam.
  • the adsorbent may be in the form of particles such as extrudate, aggregates, tablets, macrospheres or granules having a desired particle range, preferably from about 4 to about 60 mesh (Standard U.S. Mesh). Less water content in the adsorbent is advantageous from the standpoint of less water contamination of the product unless water is the desorbent.
  • the adsorbent may be employed in the form of a dense fixed bed which is alternatively contacted with a feed mixture and a desorbent material in which case the process will be only semi- continuous.
  • a set of two or more static beds of adsorbent may be employed with appropriate valving so that a feed mixture can be passed through one or more adsorbent beds of a set while a desorbent material can be passed through one or more of the other beds in a set.
  • the flow of a feed mixture and a desorbent material may be either up or down through an adsorbent in such beds. Any of the conventional apparatus employed in static bed fluid-solid contacting may be used.
  • Moving bed and simulated moving bed flow systems have a much greater separation efficiency than fixed bed systems and are therefore preferred.
  • the retention and displacement operations are continuously taking place which allow both continuous production of an extract and a raffinate stream and the continual use of feed and displacement fluid streams.
  • One preferred embodiment of this process utilizes what is known in the art as the simulated moving bed countercurrent flow system. In such a system, it is the progressive movement of multiple liquid access points down an adsorbent chamber that simulates the upward movement of adsorbent contained in the chamber.
  • a simulated moving bed flow system suitable for use in the process of the present invention is the co- current high efficiency simulated moving bed process disclosed in U.S. Patent No. 4,402,832, the disclosure of which is incorporated by reference herein.
  • At least a portion of the extract output stream will pass into a separation means wherein at least a portion of the desorbent material can be separated at separating conditions to produce an extract product containing a reduced concentration of desorbent material.
  • at least a portion of the raffinate output stream will also be passed to a separation means wherein at least a portion of the desorbent material can be separated at separating conditions to produce a desorbent stream which can be reused in the process and a raffinate product containing a reduced concentration of desorbent material.
  • the concentration of desorbent material will be less than about 5 vol. % and more preferably less than about 1 vol. %.
  • the separation means will typically be a fractionation column, the design and operation of which is well known to the separation art.
  • liquid-phase operation is preferred for this process because of the lower temperature, lower energy requirements, smaller equipment size and because of the higher yields of an extract product that can be obtained with liquid- phase operation over those obtained with vapor-phase operation.
  • Adsorption conditions will include a temperature range of from about 20°C to about 250°C, with about 50°C to about 200°C being more preferred, and a pressure sufficient to maintain liquid phase.
  • Desorption conditions will include the same range of temperatures and pressures as used for adsorption conditions.
  • the size of the units which can utilize the process of this invention can vary anywhere from those of pilot-plant scale (see, for example, U.S. Patent No. 3,706,812) to those of commercial scale and can range in flow rates from as little as a few cubic centimeters an hour up to many thousand gallons per hour.
  • this invention relates in part to a process for separating epsilon caprolactam from a mixture comprising epsilon caprolactam and one or more epsilon caprolactam isomers selected from the group consisting of 4-ethyl-2-pyrrolidinone, 5-methyl- 2-piperdinone, 3-ethyl-2-pyrrolidinone and 3-methyl-2-piperdinone or octahydrophenazine which process comprises providing an initial solution containing a non-eutectic mixture of epsilon caprolactam and one or more epsilon caprolactam isomers selected from the group consisting of 4-ethyl-2-pyrrolidinone, 5-methyl-2-piperdinone, 3-ethyl- 2-pyrrolidinone and 3-methyl-2-piperdinone or octahydrophenazine, which mixture has a composition in the compositional region where only epsilon caprolactam crystal
  • a further optional step involves adsorption separation of the epsilon caprolactam from a solution thereof so as to isolate the desired epsilon caprolactam in an even purer form as described hereinabove. may also be employed solely as described above.
  • Suitable solutions can be provided by using liquid epsilon caprolactam or by melting solid epsilon caprolactam (when melt crystallization is employed). However, suitable solutions usually consist of the epsilon caprolactam dissolved in an appropriate solvent (e.g., in the solvent in which the adsorption separation was conducted). Any solvent which will dissolve the epsilon caprolactam may be used.
  • Suitable solvents are methanol, ethyl ether, cyclopentane, acetone, methyl acetate, isopropyl ether, hexane, methyl cyclopentane, ethyl acetate, ethanol, benzene, cyclohexane, acetonitrile, propanol, propionitrile, water, toluene, cycloheptane, ethylbenzene, p-xylene, cyclooctane, ketones (e.g., acetone), esters (e.g., ethyl acetate), hydrocarbons (e.g., toluene), nitrohydrocarbons (e.g., nitrobenzene) and ethers [e.g., tetrahydrofuran (THF) and glyme].
  • methanol ethyl ether
  • cyclopentane acetone
  • a mixture of two or more solvents can be employed to maximize the purity and yield of the desired epsilon caprolactam.
  • the solution used may also contain other materials present in the crude reaction product of the epsilon caprolactam-forming reaction (e.g., catalyst and byproducts).
  • the concentration of the epsilon caprolactam in the solvent solution will be limited by the solubility of epsilon caprolactam in the solvent.
  • Illustrative crystallization techniques useful in this invention include solution and melt crystallization such as disclosed in U.S. Patent Nos. 5,430,194 and 5,675,022, the disclosures of which are incorporated herein by reference.
  • the solution containing the epsilon caprolactam is maintained under conditions such that the solubility limit of the desired epsilon caprolactam is exceeded.
  • conditions include addition of a non-solvent to the solution, removal of any solvent from the solution and, preferably, cooling the solution (including vacuum cooling the solution). Combinations of these conditions can be used to effect the desired crystallization.
  • This invention is applicable to the separation of epsilon caprolactam from a mixture containing epsilon caprolactam and the corresponding isomers of epsilon caprolactam, provided the mixture is in the compositional region where only epsilon caprolactam crystallizes on cooling of solution of the mixture.
  • Suitable mixtures include mixtures of conglomerate epsilon caprolactam compounds (illustrated by Fig. 10 which is discussed below).
  • Fig. 10 is a phase diagram of two substances, X (i.e., isomers of epsilon caprolactam) and Y (i.e., epsilon caprolactam).
  • X i.e., isomers of epsilon caprolactam
  • Y i.e., epsilon caprolactam
  • area (i.e., compositional region) I represents an unsaturated solution containing X and Y
  • area (i.e., compositional region) II corresponds to the coexistence of crystals of substance Y and the saturated solution containing X and Y
  • area (i.e., compositional region) III represents the coexistence of crystals of substance X and the saturated solution containing X and Y
  • area (i.e., compositional region) IV corresponds to mixtures of crystals of substances X and Y.
  • the curve separating areas (i.e., compositional regions) I and II is the solubility curve for substance Y
  • the curve separating areas (i.e., compositional regions) I and III is the curve for phase equilibrium between solid X and the corresponding solution containing X and Y.
  • the curves intersect at point E, where solid X, solid Y and a solution with composition E, that is saturated with both X and Y are in equilibrium.
  • Points t x and ty are the melting points of pure components X and Y, respectively.
  • the weight ratio of the maximum obtainable amount of crystals of Y to mother liquor E is given by the ratio of segments EG : GH.
  • Point E is called the eutectic point
  • temperature tE is the eutectic temperature
  • the mixture of substances X and Y with composition corresponding to point E is a eutectic mixture.
  • the crystallization is conducted using solutions containing non-eutectic epsilon caprolactam mixtures in the compositional region where only the desired epsilon caprolactam is obtained by crystallization.
  • the relative concentration of the epsilon caprolactam, the uniformity of solution temperature, the cooling rate and the cooling temperature are controlled so that the concentration of the epsilon caprolactam remains in the region where only the desired epsilon caprolactam crystallizes.
  • the relative concentration of epsilon caprolactam in order to crystallize only component Y, the relative concentration of epsilon caprolactam must be controlled to be to the right of eutectic concentration (E).
  • E eutectic concentration
  • the epsilon caprolactam mixtures useful in the process of this invention can have any composition other than the composition at which the mixture is eutectic (i.e., the mixtures are non-eutectic), provided the composition is in the region where only the desired epsilon caprolactam crystallizes on cooling the mixture.
  • the reason for the requirement of using non-eutectic mixtures is that unacceptably large amounts of the undesired isomers usually crystallize from eutectic mixtures.
  • solutions containing the epsilon caprolactam are cooled to effect crystallization of the desired epsilon caprolactam.
  • the temperature of the solution can be raised slightly after the crystals initially form to a temperature just below the initial crystallization temperature and then the temperature can be lowered again. This technique causes the smaller crystals to redissolve and the larger crystals to grow still larger with the result that better generation of the crystals from the solution is achieved. Crystallization temperature will effect both product purity and yield in that lower temperatures produce higher yields. Vacuum cooling can be used in the practice of this invention.
  • the crystallization can, if desired, be conducted by cooling in stages. That is, the initial solution of the epsilon caprolactam can be cooled to a temperature at which the desired epsilon caprolactam crystallizes and held at that temperature until crystallization is complete. Then the crystals can be filtered from the remaining solution to produce a filtrate and the filtrate can be again cooled to crystallize additional amounts of the desired epsilon caprolactam.
  • the cooling- crystallization-filtration-cooling sequence can be repeated as often as desired.
  • the advantage of operating in stages is increased yield of the desired epsilon caprolactam. It is desirable to remove some of the solvent between each cooling stage.
  • the crystallization of the desired epsilon caprolactam can be achieved using any convenient apparatus.
  • a preferred apparatus is a falling film crystallizer such as is disclosed in U.S. Patent 3,621,664 and that apparatus contains vertical (usually metallic) wall surfaces which are cooled from the opposite wall surface.
  • the liquid phase i.e., the solution of the epsilon caprolactam
  • the separation is superior to that obtained when the liquid phase fills the entire cross section of the means, such as a pipe, down which it flows, the wetted circumference and the quantity of flow for the one case being equal to those of the other.
  • Patent 3,621,664 shows that a distribution coefficient approaching the best possible value is obtainable with film flow, when the crystallization rate is on the order of one centimeter per hour, as would be required in a large scale operations and, when the molecular diffusion coefficient in the liquid phase is on the order of 10"° " centimeters ⁇ /second; whereas in the other case the distribution coefficient is close to one, indicating virtually no separation. If good separation is wanted in the other case, the Reynolds Number must be raised, which necessitates a larger flow and greater power consumption, particularly with viscous liquids, rendering operation uneconomical.
  • the cooled vertical walls of the crystallizer are, in a preferred embodiment, in the form of tube bundles having any desired number of vertical, parallel tubes, the liquid being introduced at the tops of the tubes by a distributor to flow down the tubes inner surfaces as a film, and the cooling medium filling the jacket surrounding the tubes.
  • the lower end of the crystallizer incorporates a tank for collecting the liquid phase.
  • the desired epsilon caprolactam crystals usually form on the inner surface of the falling film crystallizer.
  • the crystals are removed by dissolving the crystals in a solvent (e.g., acetone) at a temperature below the melting point of the desired crystals to avoid substantial degradation of the desired crystals.
  • a solvent e.g., acetone
  • the separation in the preferred crystallization apparatus may be improved during crystallization by periodically briefly heating (or cooling, in certain applications) the fluid phase before it enters the crystallizer. This measure yields a smooth crystal surface and avoids dendritic or uneven crystal growth with the attendant undesirable trapping of mother liquid within the crystal layer.
  • Crystallization in the above-mentioned preferred crystallization apparatus is conveniently carried out in a single apparatus in such a manner that single crystallizations are cyclically repeated, beginning with the step of the highest concentration of impurity or impurities and advancing to the step of the desired component in its purest form.
  • the small amount of mother liquor (i.e., solution of the epsilon caprolactam) held on the surfaces of the crystallizer only slightly contaminates the crystallization of the succeeding step and going from the "purest" step to the "least pure” step, when ending one cycle and starting another, does not influence the separation.
  • the crystallization process can be conducted in the preferred crystallization apparatus in an inert atmosphere.
  • the crystals of the final step can be further purified by distillation or partial melting and the less pure separated substance returned to the final step.
  • the surface on which crystallization occurs can be cooled by flowing a heat exchange medium, in the form of a film, over the opposite surface of the crystallizer wall. This surface can be vertical, horizontal, or at any angle there between.
  • the crystals of the desired epsilon caprolactam produced by the process of this invention contain considerably less of the other impurities than is contained the starting liquid epsilon caprolactam. However, some of the other impurities may be present in the crystals due to occlusion, incomplete draining or entrainment of the solution from which the crystals are formed. Thus, the process of this invention provides epsilon caprolactam having very high purity. Purities preferably greater than 98%, and more preferably greater than 99%, can be obtained by the process of this invention.
  • the primary benefit of this technology is that adsorption works best when the purity of the feed stream is from about 10 to about 95% epsilon caprolactam and it is desired to achieve about 95 to 99.5% purity. Crystallization works best when the feed is as pure as possible and it is desired to achieve purities greater than about 99.5%.
  • Another benefit of the coupling technology is that it allows for purification of epsilon caprolactam from solutions where the concentration of epsilon caprolactam is less than or equal to that of the eutectic composition.
  • the mother liquor is either disposed or reworked to improve the yields.
  • the mother liquor can be recycled back to the adsorption process for reuse.
  • the coupling technology also allows for less solvent being employed, smaller adsorption columns and, as indicated above, higher purities.
  • the coupling of adsorption separation with crystallization may be conducted with the raffinate or the extract.
  • an advantage exists over purifying the extract because the amount of solvent in the raffinate is typically less than the extract. Hence, solvent recovery costs are decreased and crystallization costs may be decreased.
  • the coupling technology can be practiced with either solution crystallization or melt crystallization.
  • melt crystallization is that one less distillation column is used. Of course, some chemical species crystallize from solution a lot easier than from the melt.
  • Fig. 11 depicts an example where the desired species is non-retentive and melt crystallization is used.
  • the feed is fed to the simulated moving bed process to which a desorptive solvent is also fed.
  • the extract, containing the undesired species is sent to a distillation column (or more preferably a flash tank if the solvent is volatile enough) to recover the solvent.
  • This solvent is recycled to the solvent feed stream.
  • the raffinate, containing the desired species is sent to a distillation column wherein the solvent is recovered and recycled back to the solvent feed system.
  • the bottoms from the column (in a heated state to keep the material fluid) are sent to a crystallizer where the desired product is further refined from the melt. The crystals are removed as the product and the mother liquor is recycled back to the feed to the simulated moving bed.
  • Fig. 12 depicts an example when melt crystallization cannot be used and solution crystallization can be.
  • the flow diagram changes somewhat and another solvent reclamation column is added.
  • the process is basically the same as depicted in Fig. 11 except the raffinate, again containing the desired species, is first sent to a crystallizer where the product is crystallized.
  • an added column can be placed to adjust the amount of solvent in the stream being fed to the crystallizer.
  • the product is then dried in a distillation column (or other dryer) whilst the mother liquor is sent to a distillation column wherein the solvent is recovered and the bottoms from the solvent recovery column are sent back to the feed to the simulated moving bed.
  • Adsorption Examples A first set of examples was performed by taking a solution consisting of 1% of caprolactam and 1% of 4-ethyl-2-pyrrolidinone (4- EP) in a solvent identified in Table A below. The resulting solution was analyzed as the starting solution. Then 5 grams of this solution was added to 1 gram of solid adsorbent, shaken at a constant temperature overnight and then analyzed. The ratio of the amount of caprolactam adsorbed onto the surface of the adsorbent to that in the solution and the ratio of the amount of 4-ethyl-2-pyrrolidinone adsorbed onto the surface of the adsorbent to that in the solution were then calculated. These ratios are known as partition coefficients.
  • a partition coefficient of 0.0 means that none of the caprolactam or 4- ethyl-2-pyrrolidinone adsorbed onto the surface of the adsorbent.
  • the temperature, solvent, adsorbent, and partition coefficients of caprolactam and 4-ethyl-2-pyrrolidinone are given in Table A.
  • Adsorbents 13X, LZ-20, LZ-10, FS-115, S115 (silicalite), 4A and 5A are available from UOP, Des Plains, Illinois.
  • Adsorbent F400 is available from Calgon Corporation, Pittsburgh, Pennsylvania.
  • small pore adsorbents specifically 4A and 5A, show little or no adsorption of 4-ethyl-2-pyrrolidinone.
  • adsorbents with a pore size of 5 Angstrom units or less are not desired for selectively adsorbing 4-ethyl-2-pyrrolidinone.
  • a second set of examples was performed by taking a solution consisting of 1% of caprolactam, 1% of 4-ethyl-2-pyrrolidinone (4-EP) and 1% of 5-methyl-2-piperdinone (5-MP) in a solvent identified in Table B below. The resulting solution was analyzed as the starting solution. Then 5 grams of this solution was added to 1 gram of solid adsorbent, shaken at a constant temperature overnight and then analyzed.
  • the ratio of the amount of caprolactam adsorbed onto the surface of the adsorbent to that in the solution, the ratio of the amount of 4-ethyl-2-pyrrolidinone adsorbed onto the surface of the adsorbent to that in the solution, and the ratio of the amount of 5-methyl-2- piperdinone adsorbed onto the surface of the adsorbent to that in the solution were then calculated as above.
  • the temperature, solvent, adsorbent, and partition coefficients of caprolactam, 4-ethyl-2- pyrrolidinone and 5-methyl-2-piperdinone are given in Table B.
  • Adsorbent S115 (silicalite) is available from UOP, Des Plains, Illinois.
  • i dsorbent F400 is available from Calgon Corporation, Pittsburgh, Pennsylvania.
  • a third set of examples was performed in a chromatographic-type column.
  • a four foot long stainless steel cubing- column was used. The column was surrounded by 1 inch tubing through which water-propylene glycol (or silicone oil) flowed from a constant temperature bath for temperature control.
  • a pump (FMI Corp.) flowed desorbent solvent to the column and through this column to a back pressure regulator at a space velocity of about 1 gram/liter/hour. The pressure was held such that the solvent was always liquid in the column.
  • the inlet to the column was valved open and about 2 grams of a solution consisting of 1% of caprolactam, 1% of 4-ethyl-2-pyrrolidinone and 1% of 5- methyl-2-piperdinone in a solvent identified in each set of tests below was injected. Aliquots of approximately 10 milliliters from the exit of the column were taken to a gas chromatograph for analysis.
  • a first set of tests was done in a V-" diameter column containing about 90 grams of S115 adsorbent. Methanol was used as the desorbent solvent. The chromatographic response from a run at 80°C is shown in Fig. 1. A similar set of tests was performed except instead of methanol as the desorbent solvent, 1% triethylamine in methanol was used as the desorbent solvent. The chromatographic response is shown in Fig. 2.
  • 1% triethylamine in methanol was used as the desorbent solvent. The same test as was just described was repeated at 110°C. The chromatographic response is shown in Fig. 3. As depicted in Fig. 3. an increased temperature can lead to a better separation.
  • adsorbent solvent methanol was used as the desorbent solvent.
  • the chromatographic response is shown in Fig. 9.
  • activated carbon can be employed as a suitable adsorbent.
  • the following examples are a combination of batch and semi-batch work.
  • samples of known amounts of caprolactam and its isomers were placed in a 4 gram bottle, the bottle contents were heated to ensure that the sample was melted, the bottle was then placed at constant temperature and crystals were allowed to form. Samples of the crystals and of the mother liquor were then acquired.
  • the semi-batch work was done with a falling film crystallizer.
  • the crystallizer used is shown in Fig. 6 of U.S. Patent 5,430,194 and consisted of a kettle (A), a jacketed column (B) ⁇ the column was a one meter long jacketed vertical tube having a one inch diameter internal opening ⁇ and (D) means for pumping (i.e., circulating) liquid from the kettle to the film device (C) at the top of the falling film crystallizer.
  • the jacket of the crystallizer was affixed to a supply of coolant (E) which flowed co-current with the falling film. That is, both the falling film and the coolant in the jacket flowed downward in a co-current fashion.
  • the crystallizer shown in Fig. 6 of U. S. Patent 5,430,194 is similar in principle of operation to that described in U.S. Patent 3,621,664.
  • the purity of the crystals was measured by removing aboxit 0.5 grams of crystal and mixing it with 1 gram of water. This solution was then taken to a HP 6890 gc/fid for the following analysis.
  • the gas chromatograph was performed with a DB-1 column, 30 millimeters long, with a 5 micron film using helium as the carrier gas.
  • the temperature program started at 60°C, and was ramped to 275°C at 20°C/min and held for 20 minutes.
  • the column pressure was constant at 20 psi.
  • Crystallization processes can be divided into two types: solution crystallization and melt crystallization.
  • Solution crystallization involves producing crystals from a solution of the solute in a solution.
  • the driving force is the solubility of the solutes in the solvent. Melt crystallization occurs when no solvent is used. The driving force the melting point of the solutes, and the solubility of one solute in the predominate solute.
  • a 90% caprolactam solution was made (acetone-free basis) by adding 4.5 grams of caprolactam with 0.5 grams of a mixture of 4- ethyl-2-pyrrolidinone (4EP) and 5-methyl-2-piperdinone (5MP) to 5 grams of acetone. This mixture was solubilized and then placed at the desired temperature and crystals were allowed to form. As above, samples of crystals were removed and analyzed. The data are shown in Table D below. The percentages in Table D are based on area counts from the gas chromatograph.
  • the purity level was raised from 93% (acetone-free basis) to more than 98% in one-stage. Furthermore, no effort was made to recrystallize and wash the crystals. These steps may lead to higher purities per stage.
  • the crystal mix appeared to have many small particles being mixed by the ultrasonics, as opposed to one big crystal that sticks to the bottle. Hence, this crystallization can occur in the presence of ultrasonics.
  • Fig. 16 shows that as the temperature of the mixture is reduced then the solubility decreases. Also, Fig. 16 shows that samples with less than about 75-80% caprolactam will need very low temperatures to crystallize.
  • the purity of the caprolactam was increased from 99.3% to about 99.9% (weighted average).
  • the first step here was to produce a caprolactam solubility curve with acetonitrile. This is shown in Fig. 18. Fig. 18 shows that acetonitrile does not solubilize caprolactam quite as readily as methanol.
  • the mixture was heated to 45°C in the kettle and pump heat exchanger.
  • the temperature of the falling film was slowly cooled to 0°C at which time crystals started growing on the inner surface of the crystallizer walls. After time was allowed for the crystals to grow to such an extent that they started to block the flow through the tube, the kettle was removed and the crystals were collected by slowly heating the crystallizer walls to about 75°C.
  • Table G shows the concentration of the caprolactam (acetonitrile-free basis) in the starting solution and the concentration of the caprolactam in the crystals.
  • the purity of the caprolactam was increased from 99.3% to about 99.9% (weighted average).
  • the mixture was heated to 80°C in the kettle and pump heat exchanger.
  • the temperature of the falling film was slowly cooled to 20°C at which time crystals started growing on the inner surface of the crystallizer walls. After time was allowed for the crystals to grow to such an extent that they started to block the flow through the tube, the kettle was removed and the crystals were collected by slowly heating the crystallizer walls to about 75°C.
  • Table H shows the concentration of the caprolactam (cyclohexane -free basis) in the starting solution and the concentration of the caprolactam in the crystals.
  • the purity of the caprolactam was increased from 99.3% to about 99.7% (weighted average).
  • caprolactam can be purified from the melt.
  • the purity of the caprolactam was increased from 99.4% to about 99.8% (weighted average).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
PCT/US1999/013407 1998-06-15 1999-06-14 Separation of epsilon caprolactam from isomers WO1999065873A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000554700A JP2002518372A (ja) 1998-06-15 1999-06-14 カプロラクタムの異性体からの分離
CA002335114A CA2335114A1 (en) 1998-06-15 1999-06-14 Separation of epsilon caprolactam from isomers
BR9911231-0A BR9911231A (pt) 1998-06-15 1999-06-14 Separação de épsilon caprolactamo de isÈmeros
KR1020007013928A KR20010052680A (ko) 1998-06-15 1999-06-14 이성체로부터 입실론 카프로락탐을 분리하는 방법
AU50825/99A AU5082599A (en) 1998-06-15 1999-06-14 Separation of epsilon caprolactam from isomers
EP99935319A EP1087942A1 (en) 1998-06-15 1999-06-14 Separation of epsilon caprolactam from isomers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/094,651 US6045703A (en) 1998-06-15 1998-06-15 Separation processes
US09/094,651 1998-06-15
US09/094,650 US6036865A (en) 1998-06-15 1998-06-15 Separation processes
US09/094,650 1998-06-15

Publications (1)

Publication Number Publication Date
WO1999065873A1 true WO1999065873A1 (en) 1999-12-23

Family

ID=26789113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013407 WO1999065873A1 (en) 1998-06-15 1999-06-14 Separation of epsilon caprolactam from isomers

Country Status (10)

Country Link
EP (1) EP1087942A1 (id)
JP (1) JP2002518372A (id)
KR (1) KR20010052680A (id)
CN (1) CN1312798A (id)
AU (1) AU5082599A (id)
BR (1) BR9911231A (id)
CA (1) CA2335114A1 (id)
ID (1) ID29234A (id)
PL (1) PL344860A1 (id)
WO (1) WO1999065873A1 (id)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677449B2 (en) 2000-05-03 2004-01-13 Basf Aktiengesellschaft Preparation of caprolactam
US6683179B2 (en) * 2000-05-03 2004-01-27 Basf Aktiengesellschaft Preparation of caprolactam
US7217818B2 (en) 2002-11-13 2007-05-15 Basf Aktiengesellschaft Purification of caprolactam
US7501047B2 (en) 2002-11-13 2009-03-10 Basf Aktiengesellschaft Method for purifying caprolactam
WO2010026147A1 (en) * 2008-09-04 2010-03-11 Dsm Ip Assets B.V. Washing of an organic phase comprising caprolactam
US8906139B2 (en) 2009-02-06 2014-12-09 Postech Academy-Industry Foundation Method for selectively isolating hydrogen or helium using a natrolite-based zeolite, and novel natrolite-based zeolite

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101070298B (zh) * 2006-05-12 2012-01-25 中国石油化工股份有限公司 一种ε-己内酰胺的提纯精制方法
KR101130120B1 (ko) * 2009-09-10 2012-03-28 포항공과대학교 산학협력단 나트로라이트계 제올라이트에 의한 수소 또는 헬륨의 선택적 분리방법 및 새로운 나트로라이트계 제올라이트
JP2011201865A (ja) * 2010-03-02 2011-10-13 Sumitomo Chemical Co Ltd ε−カプロラクタムの製造方法
CN108658863A (zh) * 2018-04-24 2018-10-16 河北美邦工程科技股份有限公司 一种利用熔融结晶法提纯己内酰胺的方法
CN111574419B (zh) * 2020-06-16 2021-08-27 河北美邦工程科技股份有限公司 己内酰胺单体的回收精制方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB824207A (en) * 1956-03-06 1959-11-25 Basf Ag Improvements in or relating to dilactams and polyamides prepared therefrom
EP0641778A1 (en) * 1993-08-20 1995-03-08 Sumitomo Chemical Company, Limited Process for purification of epsilon-caprolactam
JPH1135554A (ja) * 1997-07-15 1999-02-09 Unitika Ltd ε−カプロラクタムの回収方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB824207A (en) * 1956-03-06 1959-11-25 Basf Ag Improvements in or relating to dilactams and polyamides prepared therefrom
EP0641778A1 (en) * 1993-08-20 1995-03-08 Sumitomo Chemical Company, Limited Process for purification of epsilon-caprolactam
JPH1135554A (ja) * 1997-07-15 1999-02-09 Unitika Ltd ε−カプロラクタムの回収方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEM. PRUM., vol. 21, no. 1, 1971, pages 18 - 21 *
CHEMICAL ABSTRACTS, vol. 130, no. 13, 29 March 1999, Columbus, Ohio, US; abstract no. 168772, URAKAWA H. ET AL: "Recovery of epsilon-caprolactam from nylon 6 depolymerization solutions" XP002119369 *
CHEMICAL ABSTRACTS, vol. 74, no. 24, 14 June 1971, Columbus, Ohio, US; abstract no. 126099, MIKULA F. ET AL: "Purification of polycaprolactam monomers of different concentration by adsorption" XP002119366 *
CHEMICAL ABSTRACTS, vol. 77, no. 18, 30 October 1972, Columbus, Ohio, US; abstract no. 115044, PRUDKUN P.T. ET AL: "Purification of caprolactam" XP002119365 *
CHEMICAL ABSTRACTS, vol. 78, no. 5, 5 February 1973, Columbus, Ohio, US; abstract no. 29648, HIRAMI M. ET AL: "Purification of recovered lactams" XP002119367 *
CHEMICAL ABSTRACTS, vol. 80, no. 6, 11 February 1974, Columbus, Ohio, US; abstract no. 30397, TAJIRI H. ET AL: "Industrial waste water treatment in closed systems. Recovery of lactam monomer from the nylon 6 processing waste" XP002119368 *
NENRYO KYOKAI-SHI, vol. 52, no. 7, 1973, pages 609 - 617 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677449B2 (en) 2000-05-03 2004-01-13 Basf Aktiengesellschaft Preparation of caprolactam
US6683179B2 (en) * 2000-05-03 2004-01-27 Basf Aktiengesellschaft Preparation of caprolactam
US7217818B2 (en) 2002-11-13 2007-05-15 Basf Aktiengesellschaft Purification of caprolactam
US7501047B2 (en) 2002-11-13 2009-03-10 Basf Aktiengesellschaft Method for purifying caprolactam
WO2010026147A1 (en) * 2008-09-04 2010-03-11 Dsm Ip Assets B.V. Washing of an organic phase comprising caprolactam
CN102143945A (zh) * 2008-09-04 2011-08-03 帝斯曼知识产权资产管理有限公司 含有己内酰胺的有机相的洗涤
US8604188B2 (en) 2008-09-04 2013-12-10 Dsm Ip Assets B.V. Washing of an organic phase comprising caprolactam
US8906139B2 (en) 2009-02-06 2014-12-09 Postech Academy-Industry Foundation Method for selectively isolating hydrogen or helium using a natrolite-based zeolite, and novel natrolite-based zeolite

Also Published As

Publication number Publication date
BR9911231A (pt) 2001-03-06
CA2335114A1 (en) 1999-12-23
AU5082599A (en) 2000-01-05
PL344860A1 (en) 2001-11-19
KR20010052680A (ko) 2001-06-25
ID29234A (id) 2001-08-16
EP1087942A1 (en) 2001-04-04
JP2002518372A (ja) 2002-06-25
CN1312798A (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
US4326092A (en) Process for the separation of meta-xylene
KR100576562B1 (ko) 물 주입에 의한 흡착 단계 및 결정화 단계를 포함하는 파라크실렌의 분리 방법
US4029717A (en) Simulated moving bed adsorption-desorption process for paraxylene recovery
US6045703A (en) Separation processes
EP1087942A1 (en) Separation of epsilon caprolactam from isomers
KR960001908B1 (ko) 2,6-디메틸나프탈렌을 분리하는 방법
EP0442181B1 (en) Separation of hydroxy paraffinic dicarboxylic acids from olefinic dicarboxylic acids
US6036865A (en) Separation processes
JP4646886B2 (ja) 2,6−ジメチルナフタレンの分離および精製方法
KR100375976B1 (ko) 고온에서의하나이상의결정화단계및흡착대역의상류에위치한하나이상의점토처리단계를포함하는파라크실렌의분리방법
JP4647572B2 (ja) 異性化反応および結晶化工程を含む2,6−ジメチルナフタレンの分離および精製方法
JPH0134214B2 (id)
US4876390A (en) Process for separating dichlorodiphenylsulfone isomers
US4996380A (en) Process for extracting meta-dichlorobenzene from isomer mixtures with mixed alkali metal exchanged X zeolite adsorbents
US4283560A (en) Bulk cyclohexanol/cyclohexanone separation by selective adsorption on zeolitic molecular sieves
US3839408A (en) Continuous purification of adiponitrile
MXPA00012366A (es) Separacion de epsilon-caprolactama desde isomeros
US4814526A (en) Selective adsorption/separation of diiodonaphthalenes
US5143685A (en) Process for purification of ortho-chlorotoluene
US4408065A (en) Process for the separation of methylparaben from wintergreen oil
US4922040A (en) Process for extracting 2,5-dichlorotoluene from isomer mixtures with sodium-L zeolite adsorbents
CA2009927A1 (en) Separation of hydroxy paraffinic dicarboxylic acids from olefinic dicarboxylic acids
JPS6364412B2 (id)
JPS6289636A (ja) パラキシレンとエチルベンゼンの分離回収方法
JPH0788324B2 (ja) 2,6―ジメチルナフタレンの分離方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809499.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU ID IL IS JP KR KZ LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999935319

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020007013928

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012366

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2335114

Country of ref document: CA

Ref document number: 2000 554700

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1999935319

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007013928

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999935319

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007013928

Country of ref document: KR